Lenalidomide induced intrahepatic cholestasis in newly diagnosed patients of multiple myeloma

被引：0

作者：

Rabindra Kumar Jena

Trupti Rekha Swain

Sandeep Sadashivrao Kansurkar

Manorama Swain

机构：

[1] S.C.B. Medical College and Hospital,Department of Clinical Hematology

[2] Cuttack,Pharmacology Department, Clinical Pharmacology Unit

[3] S.C.B. Medical College and Hospital,Medicine Department

[4] Cuttack,Department of Biochemistry

[5] S.C.B. Medical College and Hospital,undefined

[6] Cuttack,undefined

[7] S.C.B. Medical College and Hospital,undefined

[8] Cuttack,undefined

来源：

European Journal of Clinical Pharmacology | 2012年 / 68卷

关键词：

Lenalidomide; Multiple myeloma; Cholestasis;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

The chemotherapeutic regimen melphalan, prednisolone, and thalidomide (MPT) is the standard of care for symptomatic multiple myeloma patients who are not eligible for high dose chemotherapy followed by autologous stem cell therapy. Lenalidomide, a newer thalidomide derivative, is 300 times more potent than thalidomide. Combined therapy using melphalan, prednisolone, and lenalidomide (MPL) is very effective with many advantages. We report here one rare adverse effect, i.e., intrahepatic cholestasis related to lenalidomide, in two patients out of a total of 65 newly diagnosed cases of multiple myeloma receiving MPL regimen in our series. As the use of lenalidomide will increase in the future for multiple myeloma and other diseases, clinicians should be aware of this entity.

引用

页码：881 / 884

页数：3

共 32 条

[1]

Richardson PG(2005)Bortezomib or high-dose dexamethasone for relapsed multiple myeloma N Engl J Med 352 2487-2498

[2]

Sonneveld P(2006)Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomized controlled trial Lancet 367 825-831

[3]

Schuster MW(2005)Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma Blood 106 4050-4053

[4]

Palumbo A(2011)Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications Leukemia 15 1950-1961

[5]

Bringhen S(2004)The evolution of thalidomide and its IMID derivative as anticancer agents Nat Rev Cancer 4 314-322

[6]

Caravita T(2010)Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients Blood 115 1343-50

[7]

Rajkumar SV(2007)Melphalan, prednisolone and linalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA—Italian Multiple Myeloma Network J Clin Oncol 25 4459-65

[8]

Hayman SR(2007)Linalidomide plus dexamethasone for relapse multiple myeloma in North America M Engl J Med 357 2133-42

[9]

Lacy MQ(2007)Lenalidomide in the treatment of multiple myeloma Am J Health Syst Pharm 64 1799-1807

[10]

Gupta D(2007)Lenalidomide-induced severe hepatotoxicity Blood 110 3814-525

← 1 2 3 4 →